retatrutide clinical trials latest A new trial from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes retatrutide peptide | peptidesskin

The percentage of participants achieving clinically meaningful thresholds (5%, 10%, 15%, 20%+ weight loss) exceeded anything previously seen with GLP-1 based therapies

GLP-1 agonists facilitate rapid weight loss, averaging 15 to 25% of body weight

Activation of the glucagon receptor has been studied in relation to lipid metabolism and energy expenditure

Its a possible outcome

Weekly GLP-1 receptor agonists typically reach steady-state concentrations after 45 weeks of regular dosing

Glucagon receptor agonism increases energy expenditure and promotes hepatic fatty acid oxidation, which may contribute to reductions in liver fat content